Inflammatory biomarkers as differential predictors of antidepressant response

International Journal of Molecular Sciences

Volumn 16, Issue 4, 2015, Pages 7796-7801

  Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Antidepressant; Biomarker; Cytokine; Inflammation; Ketamine; Predictor; Response

Indexed keywords

ALGORITHM; ANTIDEPRESSANT ACTIVITY; HUMAN; IMMUNE SYSTEM; INFLAMMATION; MAJOR DEPRESSION; REVIEW; TREATMENT RESPONSE; BLOOD; DEPRESSIVE DISORDER, MAJOR; METABOLISM; TREATMENT OUTCOME;

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; KETAMINE;

ANTIDEPRESSIVE AGENTS; BIOMARKERS; C-REACTIVE PROTEIN; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; HUMANS; INFLAMMATION; KETAMINE; TREATMENT OUTCOME;

EID: 84927667387     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16047796     Document Type: Review

References (30)

1. World Health Organization (WHO) Depression. Fact sheet No. 369/October 2012. Available online: http://www.who.int/mediacentre/factsheets/fs369/en/index.html (accessed on 10 March 2015).
2. Leuchter, A.F.; Cook, I.A.; Hamilton, S.P.; Narr, K.L.; Toga, A.; Hunter, A.M.; Faull, K.; Whitelegge, J.; Andrews, A.M.; Loo, J.; et al. Biomarkers to predict antidepressant response. Curr. Psychiatry Rep. 2010, 12, 553-562.
3. Martins-de-Souza, D.; Harris, L.W.; Guest, P.C.; Turck, C.W.; Bahn, S. The role of proteomics in depression research. Eur. Arch. Psychiatry Clin. Neurosci. 2010, 260, 499-506.
4. Breitenstein, B.; Scheuer, S.; Holsboer, F. Are there meaningful biomarkers of treatment response for depression? Drug Discov. Today 2014, 19, 539-561.
5. Hashimoto, K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 2009, 61, 105-123.
6. Miller, A.H.; Maletic, V.; Raison, C.L. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65, 732-741.
7. Raison, C.L.; Lowry, C.A.; Rook, G.A. Inflammation, sanitation, and consternation: Loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch. Gen. Psychiatry 2010, 67, 1211-1224.
8. Dantzer, R.; O'Connor, J.C.; Freund, G.G.; Johnson, R.W.; Kelly, K.W. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9, 46-57.
9. O'Connor, J.C.; Lawson, M.A.; André, C.; Moreau, M.; Lestage, J.; Castanon, N.; Kelley, K.W.; Dantzer, R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 2009, 14, 511-522.
10. Ma, M.; Ren, Q.; Zhang, J.C.; Hashimoto, K. Effects of brilliant blue G on serum tumor necrosis factor-α levels and depression-like behavior in mice after lipopolysaccharide administration. Clin. Psychopharmacol. Neurosci. 2014, 12, 31-36.
11. Zhang, J.C.; Wu, J.; Fujita, Y.; Yao, W.; Ren, Q.; Yang, C.; Li, S.X.; Shirayama, Y.; Hashimoto, K. Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int. J. Neuropsychopharmacol. 2015, 18, 1-12.
12. Ohgi, Y.; Futamura, T.; Kikuchi, T.; Hashimoto, K. Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol. Biochem. Behav. 2013, 103, 856-859.
13. Dowlati, Y.; Herrmann, N.; Swardfager, W.; Liu, H.; Sham, L.; Reim, E.K.; Lanctôt, K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67, 446-457.
14. Shelton, R.C.; Claiborne, J.; Sidoryk-Wegrzynowicz, M.; Reddy, R.; Aschner, M.; Lewis, D.A.; Mirnics, K. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol. Psychiatry 2011, 16, 751-762.
15. Howren, M.B.; Lamkin, D.M.; Suls, J. Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom. Med. 2009, 71, 171-186.
16. Valkanova, V.; Ebmeier, K.P.; Allan, C.L. CRP, IL-6 and depression: A systematic review and meta-analysis of longitudinal studies. J. Affect. Disord. 2013, 150, 736-744.
17. Uher, R.; Tansey, K.E.; Dew, T.; Maier, W.; Mors, O.; Hauser, J.; Dernovsek, M.Z.; Henigsberg, N.; Souery, D.; Farmer, A.; McGuffin, P. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am. J. Psychiatry 2014, 171, 1278-1286.
18. Martino, M.; Rocchi, G.; Escelsior, A.; Fornaro, M. Immunomodulation mechanism of antidepressants: Interactions between serotonin/norepinephrine balance and Th1/Th2 balance. Curr. Neuropharmacol. 2012, 10, 97-123.
19. Hashimoto, K. Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine. Expert Rev. Neurother. 2011, 11, 33-36.
20. Aan Het Rot, M.; Zarate, C.A. Jr; Charney, D.S.; Mathew, S.J. Ketamine for depression: Where do we go from here? Biol. Psychiatry 2012, 72, 537-547.
21. Krystal, J.H.; Sanacora, G.; Duman, R.S. Rapid-acting glutamtergic antidepressants: The path to ketamine and beyond. Biol. Psychiatry 2013, 73, 1133-1141.
22. Zarate, C.A., Jr.; Mathews, D.C.; Furey, M.L. Human biomarkers of rapid antidepressant effects. Biol. Psychiatry 2013, 73, 1142-1155.
23. Hashimoto, K.; Malchow, B.; Falkai, P.; Schmitt, A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263, 367-377.
24. Hashimoto, K. The R-stereoisomer of ketamine as an alternative for ketamine for treatment-resistant major depression. Clin. Psychopharmacol. Neurosci. 2014, 12, 72-73.
25. Yang, C.; Hashimoto, K. Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology (Berl.) 2014, 231, 2041-2042.
26. Hillhouse, T.M.; Porter, J.H. A brief history of the development of antidepressant drugs: From monoamines to glutamate. Exp. Clin. Psychopharmacol. 2015, 23, 1-21.
27. De Wilde, K.E.; Levitch, C.F.; Murrough, J.W.; Mathew, S.J.; Iosifescu, D.V. The promise of ketamine for treatment-resistant depression: Current evidence and future directions. Ann. N. Y. Acad. Sci. 2015, doi:10.1111/nyas.12646.
28. Abdallah, C.G.; Averill, L.A.; Krystal, J.H. Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann. N. Y. Acad. Sci. 2015, doi:10.1111/nyas.12718.
29. Hashimoto, K. Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine. Psychopharmacology (Berl.) 2014, 231, 4081-4082.
30. Yang, J.J.; Wang, N.; Yang, C.; Shi, J.Y.; Yu, H.Y.; Hashimoto, K. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression. Biol. Psychiatry 2015, 77, e19-e20.